ClinicalTrials.gg
Not yet recruitingNCT07723573CFOUpdated Jul 23, 2026

Comparing Effects of Custom Foot Orthotic Intervention to Foot-Core Training Protocol on Lower Extremity Kinematics in Runners With Pes Planus

An interventional study of Custom foot orthoses and Intrinsic foot muscle strengthening exercises in Pes Planus and Running Related Injuries, sponsored by Dalhousie University. Not yet recruiting at 1 site in Canada. Open to participants aged 18 Years to 30 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-07-23.

Sponsored by Dalhousie University · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
24
Allocation
Not applicable
Ages
18 Years to 30 Years
Sex
All
01

Study summary

Running is a full body movement that requires the feet to support the body and absorb forces greater than the individual's body weight in a repeated fashion. If the musculoskeletal structures of the feet cannot withstand and disperse the force applied, injury and dysfunction will occur. Without the inherent support of the foot musculature, ligaments are strained, and bones of the foot and ankle must absorb all forces, directly. When the medial longitudinal arch cannot be supported, the entire structure collapses, causing the foot to pronate. These postural signs indicate pes planus, or flat feet. Custom foot orthoses (CFOs) are commonly used to manage pes planus and research within the last 25 years has not provided clear insight on how CFOs influence running mechanics of joints and segments proximal to the foot (knee and hip). Additionally, CFO intervention has not been compared to exercise programming that focuses on strengthening the muscles that provide the foot with intrinsic strength. This study will provide insight on how these two interventions may influence foot biomechanics in the pes planus foot. We are hopeful that our findings can help to inform rehabilitation professionals in how different interventions can alter biomechanical outcomes related to pes planus. Previous literature also commonly focuses on an aging or sedentary individuals, while this study will focus on young active participants with a pes planus foot type.

Healthy recreational runners between the ages of 18-35 years old with pes planus will be recruited to participate. Participants will be randomly appointed to one of two groups: 1) the CFO group will wear CFOs for 8 weeks; and 2) the exercise group will be assigned an exercise protocol to complete each day for eight weeks. Participation will consist of completion of a prolonged run protocol in two testing sessions, pre- and post-intervention, and compliance to their assigned intervention. Three-dimensional kinematic data will be collected using a 10-camera motion capture system (Qualisys). For each data collection session, passive reflective markers will be placed on the participant both lower extremities, and participants will be instrumented with a heart rate (HR) monitor. The prolonged run protocol will consist of a five-minute warm-up phase, where participants will choose a comfortable running speed, with a desired HR at approximately 120 beats per minute (bpm). After the warm-up, participants will be permitted to stretch if desired, as they would before a typical run. Once ready, the participant will select a comfortable running pace that best represents their typical training pace. Running speed will be intermittently increased. A member of the research team will monitor the participant throughout the trial to check their HR, ask them to rate their perceived exertion on Borg's RPE scale (which will be displayed in front of them), and ask them to rate any pain they may be feeling on a scale from 1-10. The prolonged run protocol will end when any of the following occurs: 1) participant HR reaches 85% of their HR max, 2) participant rates the activity a score of 17 (very hard) on Borg's RPE Scale, or 3) the participant gives a 7/10 pain rating. Once the protocol has ended, participants will enter a cool-down phase where they will jog or walk until HR lowers. Participants will be able to stretch again following the protocol if desired.

02

Conditions studied

  • Pes Planus
  • Running Related Injuries

Browse trials for

03

In context

Flatfoot

173 studies on the registry are indexed under Flatfoot; 44 are open to participants now.

This study's planned enrollment of 24 is below the median of 40 across 122 interventional studies indexed under Flatfoot.

Browse Flatfoot studies →

Lead sponsor

Dalhousie University is the lead sponsor of 52 studies on the registry; 10 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 30 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • healthy recreational runners
  • aged 18-30 years old
  • pes planus foot type as characterized by the Foot Posture Index

Exclusion criteria

Exclusion Criteria:

  • Individuals having any cardiovascular or neurological illnesses
  • Individuals having any chronic musculoskeletal diseases such as rheumatoid arthritis or osteoarthritis
  • Individuals who have suffered a running-related injury in the 6 months leading up to the study
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
24 participants (estimated)

Study arms

  • Experimental
    Pes planus

    Individuals who have been classified as having a pes planus foot type using the Foot Posture Index.

    Device: Custom foot orthoses · Behavioral: Intrinsic foot muscle strengthening exercises

Interventions

  • DeviceCustom foot orthoses

    Custom foot orthoses constructed from a neutral suspension cast

  • BehavioralIntrinsic foot muscle strengthening exercises

    An 8 week, intrinsic foot muscle strengthening program focusing on the intrinsic foot muscles that stabilize the medial longitudinal arch of the foot.

06

What researchers measure

Primary outcomes

  1. Standing static, arch height

    The static standing arch height will be calculated using motion capture.

    Time frame: From enrollment to the end of the interventions at 8 weeks

  2. Maximum three dimensional joint angles of the hip, knee and ankle

    Joint angle maxima for the hip, knee and ankle during the stance phase of running.

    Time frame: From enrollment to the end of each intervention at 8 weeks

07

Study locations

1 site
  • School of Health and Human Performance
    Halifax, Nova Scotia B3H4R2, Canada
08

References and documents

Publications

  • MacLean C, Davis IM, Hamill J. Influence of a custom foot orthotic intervention on lower extremity dynamics in healthy runners. Clin Biomech (Bristol). 2006 Jul;21(6):623-30. doi: 10.1016/j.clinbiomech.2006.01.005. Epub 2006 Apr 5. PubMed 16603287 ↗
  • Maclean CL, Davis IS, Hamill J. Influence of running shoe midsole composition and custom foot orthotic intervention on lower extremity dynamics during running. J Appl Biomech. 2009 Feb;25(1):54-63. doi: 10.1123/jab.25.1.54. PubMed 19299830 ↗
  • MacLean CL, Davis IS, Hamill J. Short- and long-term influences of a custom foot orthotic intervention on lower extremity dynamics. Clin J Sport Med. 2008 Jul;18(4):338-43. doi: 10.1097/MJT.0b013e31815fa75a. PubMed 18614885 ↗
  • MacLean CL, van Emmerik R, Hamill J. Influence of custom foot orthotic intervention on lower extremity intralimb coupling during a 30-minute run. J Appl Biomech. 2010 Nov;26(4):390-9. doi: 10.1123/jab.26.4.390. PubMed 21245498 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Sep 2026; primary completion for Oct 2027, 13 months later.

Of 89 non-industry interventional studies with no phase under Flatfoot, half reached primary completion within 7 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 15. This study's planned 13 months is above that.

Counting every sponsor, half of 89 studies reached it within 7 months; a quarter within 2 and three quarters within 15.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 15, 2026
First posted
Jul 23, 2026
StartEst.
Sep 1, 2026
Primary completionEst.
Oct 31, 2027
CompletionEst.
Aug 31, 2028
Last update
Jul 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 23, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07723573
Lead sponsor
Dalhousie University
Responsible party
Christopher MacLean (Instructor, Dalhousie University) — Principal investigator
First posted
Jul 23, 2026
Start date
Sep 1, 2026 (estimated)
Primary completion
Oct 31, 2027 (estimated)
Completion
Aug 31, 2028 (estimated)
Last update
Jul 23, 2026

Study contacts

Christopher L MacLean, Ph.D.
Contact
christopher.maclean@dal.ca
6043519030
Jayde Corkum, B.Sc.
Contact
jaydecorkum@dal.ca

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion